Is Adagene Inc. (ADAG) a Buy, Sell, or Hold?
NASDAQ : ADAG
Adagene Inc.
$3.75 USD
-$0.14 (-3.6%)
- Volume
- 291.7K
- Average Volume
- 259.33K
- Market Capitalization
- $141.18M
- P/E Ratio
- -7.95
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $4.85
- Year Low
- $1.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.07
Company Overview
NASDAQ
Peter Luo
Biotechnology
Healthcare
ADAG
128
CN
USD
Liquidity Metrics
0.18
3.07
3.07
2.96
0.00
Sales & Valuation
$7.67M
18.35
4.02
-8.98
-0.41
Profitability
-$0.46
-$17.61M
-229.49%
-233.37%
-48.20%
-22.56%
P/E Metrics
-7.95
-0.08
-0.08
Analyst Price Target & Rating
$10.00
$10.00
$10.00
2/5
5 Analysts
-62.50%
Financial Health Scores
-5.22
5/9
$52.2M
$78.26M
$42.91M
-$54.08M
Key Metrics (TTM)
$78.19M
10.16
-3.74
3.07
-48.20%
-36.34%
-11.97%
-10.73%
-1806 days
Company Executives
| Name | Title |
|---|---|
| Yan Li | Senior Vice President of Bioinformatics & Information Technology |
| Guizhong Liu | Senior Vice President of Early Drug Discovery |
| Mickael Chane-Du | Chief Strategy Officer |
| Qinghai Zhao | Chief Manufacturing Officer |
| Chunfang Gu | Executive Director of Finance |
| Alexander Goergen | Vice President & Head of Business Development |
| Ling Zhou | Executive Director & Head of Human Resources |
| Xiaohong She | Senior Vice President & Head of Clinical Operations |
| Man Kin Tam | Chief Financial Officer & Director |
| Peter Luo | Co- Founder, Chairman, Chief Executive Officer and President of R&D |
Poll Results
No votes yet today — be the first to share your view!
About Adagene Inc. (NASDAQ:ADAG) Stock
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid ... tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
2026-08-12 07:30:00
Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen has been established
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
2026-06-05 13:00:30
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adagene (ADAG) This Year?
2026-06-02 10:41:10
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
2026-05-19 17:08:02
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
Adagene to Participate in Two Upcoming Investor Conferences
2026-05-12 08:30:00
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
Frequently Asked Questions
-
What is the current Adagene Inc. (ADAG) stock price?
-
Adagene Inc.(NASDAQ:ADAG) stock price is $3.75 in the last trading session. During the trading session, ADAG stock reached the peak price of $4.85 while $1.3 was the lowest point it dropped to. The percentage change in ADAG stock occurred in the recent session was --3.6% while the dollar amount for the price change in ADAG stock was -$0.14.
-
ADAG's industry and sector of operation?
-
The NASDAQ listed ADAG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADAG?
-
Yan Li | Senior Vice President of Bioinformatics & Information Technology
Guizhong Liu | Senior Vice President of Early Drug Discovery
Mickael Chane-Du | Chief Strategy Officer
Qinghai Zhao | Chief Manufacturing Officer
Chunfang Gu | Executive Director of Finance -
How many employees does ADAG have?
-
Number of ADAG employees currently stands at 128. ADAG operates from Building C14, Suzhou, JS 215123, CN.
-
Link for ADAG official website?
-
Official Website of ADAG is: https://www.adagene.com
-
How do I contact ADAG?
-
ADAG could be contacted at phone #86 512 8777 3632 and can also be accessed through its website. ADAG operates from Building C14, Suzhou, JS 215123, CN.
-
How many shares of ADAG are traded daily?
-
The average number of ADAG shares traded daily for last 3 months was 259.33K.
-
What is the market cap of ADAG currently?
-
The market value of ADAG currently stands at $141.18M with its latest stock price at $3.75